Want to see DE:BNN full AI Analyst Report?
BNN Stock Chart & Stats
€2.50
€0.00(0.00%)
At close: 4:00 PM EST
€2.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.95 - €3.89
Previous CloseN/A
Volume750.00
Average Volume (3M)10.93K
Market Cap
€60.74M
Enterprise Value€75.58
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€4.82M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding21,847,494
10 Day Avg. Volume22,707
30 Day Avg. Volume10,926
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)€52.53M
Bulls Say, Bears Say
Bulls Say
Scale Of RevenuesA trailing-twelve-month revenue base of roughly €61.3m provides a tangible commercial footprint and operating scale, supporting ongoing R&D and commercialization. That scale can help absorb fixed costs, enable product iterations, and provide a platform to pursue higher-margin offerings if growth is restored.
Gross Margin ResilienceA TTM gross margin near 27.6% indicates underlying product or service economics that can support profitability if operating expenses are controlled and revenue stabilizes. Durable gross margins create room for investment in development and commercialization while improving the leverage potential as sales scale.
Relatively Modest Reported DebtReported debt of about €4.8m is modest in absolute terms relative to the revenue base, limiting near-term interest burden and complexity of capital structure. Lower contractual debt keeps refinancing needs simpler and can make external funding or restructuring less constrained than high-leverage peers.
Bears Say
Persistent Cash BurnConsistent negative operating cash flow (~-€7.4m) and free cash flow (~-€9.0m) point to ongoing cash consumption that will require continued financing or material operational improvement. Persistent burn reduces runway, increases dilution risk, and constrains the firm's ability to fund R&D or commercial expansion without new capital.
Negative Stockholders' EquityNegative shareholders' equity is a structural balance-sheet weakness that signals accumulated losses and impairs financial flexibility. It can restrict access to debt financing, raise covenants/default risk, and limit strategic options, making the firm more dependent on equity raises or asset sales to sustain operations.
Declining Revenue TrendA sharp year-over-year revenue decline (RevenueGrowth ~-9.17%) indicates demand or execution issues that undermine operating leverage. Falling top-line reduces the company's ability to absorb fixed costs, slows margin improvement, and lengthens the timeline to reach sustainable profitability absent structural fixes or new revenue streams.
BNN FAQ
What was B.R.A.I.N. Biotechnology Research and Information Network AG’s price range in the past 12 months?
B.R.A.I.N. Biotechnology Research and Information Network AG lowest stock price was €1.95 and its highest was €3.89 in the past 12 months.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap?
B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap is €60.74M.
When is B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date?
B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date is Aug 27, 2026 which is in 32 days.
How were B.R.A.I.N. Biotechnology Research and Information Network AG’s earnings last quarter?
B.R.A.I.N. Biotechnology Research and Information Network AG released its earnings results on May 28, 2026. The company reported -€0.29 earnings per share for the quarter, missing the consensus estimate of -€0.09 by -€0.2.
Is B.R.A.I.N. Biotechnology Research and Information Network AG overvalued?
According to Wall Street analysts B.R.A.I.N. Biotechnology Research and Information Network AG’s price is currently Overvalued.
Does B.R.A.I.N. Biotechnology Research and Information Network AG pay dividends?
B.R.A.I.N. Biotechnology Research and Information Network AG does not currently pay dividends.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate?
B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does B.R.A.I.N. Biotechnology Research and Information Network AG have?
B.R.A.I.N. Biotechnology Research and Information Network AG has 21,847,494 shares outstanding.
What happened to B.R.A.I.N. Biotechnology Research and Information Network AG’s price movement after its last earnings report?
B.R.A.I.N. Biotechnology Research and Information Network AG reported an EPS of -€0.29 in its last earnings report, missing expectations of -€0.09. Following the earnings report the stock price went up 2.062%.
Which hedge fund is a major shareholder of B.R.A.I.N. Biotechnology Research and Information Network AG?
Currently, no hedge funds are holding shares in DE:BNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
B.R.A.I.N. Biotechnology Research and Information Network Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
B.R.A.I.N. Biotechnology Research and Information Network AG
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of advanced biological solutions. These include enzymes, biocatalysts, microorganisms, and naturally derived active compounds, catering to the chemical industry across Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two distinct segments: BioScience and BioIndustrial. The BioScience division is dedicated to uncovering and developing bioactive natural ingredients, such as sugar alternatives, taste modifiers, and other nature-based active components for diverse applications in the food, animal nutrition, skincare, cosmetics, and broader chemical sectors. Concurrently, the BioIndustrial segment focuses on identifying and optimizing enzymes and biocatalysts critical for manufacturing food and beverages, medical wound care products, lubricants, as well as for starch processing and bioethanol production. This segment also engineers microorganisms to serve as functional biomass for optimizing industrial manufacturing processes, converting greenhouse gas CO2 into a valuable industrial raw material, and facilitating the extraction of precious and rare earth metals. Furthermore, BRAIN Biotech AG has established strategic alliances with AnalytiCon Discovery GmbH and Roquette to jointly develop natural sweeteners and enhanced sweet taste solutions.